BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Diel R, Lampenius N, Nienhaus A. Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations. PharmacoEconomics 2015;33:783-809. [DOI: 10.1007/s40273-015-0267-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Nsengiyumva NP, Campbell JR, Oxlade O, Vesga JF, Lienhardt C, Trajman A, Falzon D, Den Boon S, Arinaminpathy N, Schwartzman K. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness. PLoS Med 2022;19:e1004032. [DOI: 10.1371/journal.pmed.1004032] [Reference Citation Analysis]
2 Tosti ME, Marceca M, Eugeni E, D'Angelo F, Geraci S, Declich S, Della Seta M, Ferrigno L, Marrone R, Pajno C, Pizzarelli S, Rosso A, De Ponte G, Mirisola C, Baglio G. Health assessment for migrants and asylum seekers upon arrival and while hosted in reception centres: Italian guidelines. Health Policy 2021;125:393-405. [PMID: 33461797 DOI: 10.1016/j.healthpol.2020.12.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lange B, Bockey A, Kern W, Rieg S. Screening for Infectious Diseases on Arrival and Integrated Healthcare for Refugees and Asylum Seekers During the First Months After Arrival. Migration, Minorities and Modernity 2019. [DOI: 10.1007/978-3-030-03155-8_6] [Reference Citation Analysis]
4 Diel R. Tuberkulose bei Migranten. Pneumologe 2018;15:14-21. [DOI: 10.1007/s10405-017-0147-5] [Reference Citation Analysis]
5 Zellweger J; TB Competence Center, Swiss Lung Association, Berne, Switzerland. Latent Tuberculosis Infection. European Respiratory & Pulmonary Diseases 2018;4:21. [DOI: 10.17925/erpd.2018.4.1.21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Owusu-Edusei K Jr, Winston CA, Marks SM, Langer AJ, Miramontes R. Tuberculosis Test Usage and Medical Expenditures from Outpatient Insurance Claims Data, 2013. Tuberc Res Treat 2017;2017:3816432. [PMID: 29326845 DOI: 10.1155/2017/3816432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Bozorgmehr K, Razum O, Saure D, Joggerst B, Szecsenyi J, Stock C. Yield of active screening for tuberculosis among asylum seekers in Germany: a systematic review and meta-analysis. Euro Surveill 2017;22:30491. [PMID: 28367795 DOI: 10.2807/1560-7917.ES.2017.22.12.30491] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
8 Turetz ML, Ma KC. Diagnosis and management of latent tuberculosis. Curr Opin Infect Dis 2016;29:205-11. [PMID: 26836374 DOI: 10.1097/QCO.0000000000000253] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
9 Auguste P, Tsertsvadze A, Court R, Pink J. A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups. Tuberculosis 2016;99:81-91. [DOI: 10.1016/j.tube.2016.04.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
10 Van den Ende J, Huits R. De tol van dodelijke infectieziekten wereldwijd. Bijblijven 2015;31:470-484. [DOI: 10.1007/s12414-015-0064-7] [Reference Citation Analysis]
11 Is PT for TB cost effective in high-risk groups? PharmacoEcon Outcomes News 2015;724:14-14. [DOI: 10.1007/s40274-015-1992-2] [Reference Citation Analysis]